JP2000500770A - Nk3拮抗物質としてのキノリン誘導体の塩 - Google Patents
Nk3拮抗物質としてのキノリン誘導体の塩Info
- Publication number
- JP2000500770A JP2000500770A JP9520160A JP52016097A JP2000500770A JP 2000500770 A JP2000500770 A JP 2000500770A JP 9520160 A JP9520160 A JP 9520160A JP 52016097 A JP52016097 A JP 52016097A JP 2000500770 A JP2000500770 A JP 2000500770A
- Authority
- JP
- Japan
- Prior art keywords
- compound
- alkyl
- formula
- salt
- ring
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
- C07D215/50—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 4
- C07D215/52—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 4 with aryl radicals attached in position 2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
- C07D215/50—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 4
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Pulmonology (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Dermatology (AREA)
- Rheumatology (AREA)
- Hospice & Palliative Care (AREA)
- Immunology (AREA)
- Psychology (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Description
Claims (1)
- 【特許請求の範囲】 1.式(I): [式中、Arは所望により置換されていてもよいフェニル、ナフチルまたはC5- 7 シクロアルクジエニル基、または、芳香族性を有し、5ないし12個の環原子を含 有し、かつ当該環または各環にS、O、Nから選択された4個までのヘテロ原子 を含み、所望により置換されていてもよい、単環または縮合環の複素環基であり ; Rは直鎖または分岐鎖のC1-8アルキル、C3-7シクロアルキル、C4-7シクロア ルキルアルキル、所望により置換されていてもよいフェニルまたはフェニルC1- 6 アルキル、OおよびNから選択された4個までのヘテロ原子を含み、所望によ り置換されていてもよい、5員のヘテロ芳香環、ヒドロキシC1-6アルキル、ア ミノC1-6アルキル、C1-6アルキルアミノアルキル、ジC1-6アルキルアミノア ルキル、C1-6アシルアミノアルキル、C1-6アルコキシアルキル、C1-6アルキ ルカルボニル、カルボキシ、C1-6アルコキシカルボニル、C1-6アルコキシカル ボニルC1-6アルキル、アミノカルボニル、C1-6アルキルアミノカルボニル、ジ C1-6アルキルアミノカルボニル、ハロゲノC1-6アルキル;または、Ar上に環 化された場合は基−(CH2)p−であり、ここでpは2または3であり; R1およびR2は同一または異なっていてもよく、独立して水素または、C1-6直 鎖もしくは分岐鎖アルキルであるか、あるいは、一緒になってnが3、4、また は5を表す−(CH2)n−基を形成するか;あるいは、R1はRと一緒になって qが2、3、4または5を表す基−(CH2)q−を形成し、 R3およびR4は、同一または異なっていてもよく、独立して水素、C1-6直鎖ま たは分岐鎖アルキル、C1-6アルケニル、アリール、C1-6アルコキシ、ヒドロキ シ、ハロゲン、ニトロ、シアノ、カルボキシ、カルボキシアミド、スルホンアミ ド、C1-6アルコキシカルボニル、トリフルオロメチル、アシルオキシ、フタル イミド、アミノ、モノ−およびジ−C1-6アルキルアミノ、 rが2、3、または4で、Tが水素またはC1-6アルキルであるか、あるいは 隣接した窒素と、VおよびV1が独立して水素または酸素であり,uが0、1ま たは2である基: を形成する−O(CH2)r−NT2; sが2、3、または4であり、Wが水素またはC1−6アルキル;ヒドロキシ アルキル、アミノアルキル、モノ−またはジ−アルキルアミノアルキル、アシル アミノ、アルキルスルホニルアミノ、アミノアシルアミノ、モノ−またはジ−ア ルキルアミノアシルアミノである−O(CH2)s−OWであり;4個までのR3 置換基はキノリン核に存在し; またはR4はアリールとしてのR5上に環化された場合は、tが1、2、または 3である基−(CH2)t−であり; R5は分岐鎖または直鎖のC1-6アルキル、C3-7シクロアルキル、C4-7シクロア ルキルアルキル、所望により置換されていてもよいアリール、または芳香族性を 有し、5ないし12個の環原子を含有し、かつ当該環または各環にS、O、Nから 選択した4個までのヘテロ原子を含み、所望により置換されていてもよい、単環 または縮合環の複素環基であり、 XはO、S、またはN−C≡Nである] で示され、その塩がアニオン型の式(I)の化合物および塩形成性カチオンから なるという特徴を持つ化合物、またはその溶媒和物。 2.式(A): St-Mt+ (A) [式中、tは整数の1、2、または3であり; Mt+は塩形成性カチオンであって; St-は請求項1記載の式(I)の適当な化合物によって提供されるアニオンであ る] で示される請求項1記載の化合物またはその溶媒和物。 3.塩形成性カチオンMt+が金属イオンまたは有機陽イオンである請求項2記 載の化合物。 4.金属塩形成性カチオンMt+がアルミニウム、アルカリ金属もしくはアルカ リ土類金属イオンから選択される請求項2記載の化合物。 5.有機塩形成性カチオンMt+がアンモニウムまたは置換されたアンモニウム イオンから選択される請求項2記載の化合物。 6.塩形成性カチオンMt+がナトリウムイオンである請求項2記載の化合物。 7.tが1または2である請求項2ないし6いずれかに1項記載の化合物。 8.(S)−(+)−N−(α−エチルベンジル)−3−ヒドロキシ−2−フ ェニル−4−キノリンカルボキシアミドナトリウム塩三二水化和物である請求項 1記載の化合物。 9.式(I)の化合物および塩形成性カチオンの供給源を混合し;しかる後、 要すれば、かく形成された塩の溶媒和物を調製することを特徴とする、請求項1 記載の化合物の製法。 10.請求項1記載の化合物、またはその医薬上許容される溶媒和物、および 医薬上許容される担体からなる医薬組成物。 11.活性のある治療物質として使用するための、請求項1記載の化合物、ま たはその医薬上許容される溶媒和物。 12.本明細書で前に開示された一次疾患、二次疾患、またはさらなる疾患の 治療のための医薬品の製造における、請求項1記載の化合物、またはその医薬上 許容される溶媒和物の使用。 13.治療および/または予防を必要としている哺乳類に、有効で無毒の医薬 上許容される量の、請求項1記載の化合物またはその医薬上許容される溶和物を 投与することを特徴とする、哺乳類における一次疾患、二次疾患、またはさらな る疾患の治療および/または予防方法。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB9524137.8 | 1995-11-24 | ||
GBGB9524137.8A GB9524137D0 (en) | 1995-11-24 | 1995-11-24 | Novel compounds |
PCT/EP1996/005210 WO1997019928A1 (en) | 1995-11-24 | 1996-11-22 | Salts of quinoline derivatives as nk3 antagonists |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2000500770A true JP2000500770A (ja) | 2000-01-25 |
JP4377454B2 JP4377454B2 (ja) | 2009-12-02 |
Family
ID=10784449
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP52016097A Expired - Fee Related JP4377454B2 (ja) | 1995-11-24 | 1996-11-22 | Nk3拮抗物質としてのキノリン誘導体の塩 |
Country Status (23)
Country | Link |
---|---|
US (3) | US6355654B1 (ja) |
EP (1) | EP0876348B1 (ja) |
JP (1) | JP4377454B2 (ja) |
KR (1) | KR19990071599A (ja) |
CN (1) | CN1207728A (ja) |
AR (1) | AR004970A1 (ja) |
AT (1) | ATE233243T1 (ja) |
AU (1) | AU722451B2 (ja) |
BR (1) | BR9611729A (ja) |
CA (1) | CA2238312A1 (ja) |
CZ (1) | CZ158198A3 (ja) |
DE (1) | DE69626416T2 (ja) |
ES (1) | ES2192621T3 (ja) |
GB (1) | GB9524137D0 (ja) |
HU (1) | HUP9903584A3 (ja) |
IL (1) | IL124352A0 (ja) |
MX (1) | MX9804106A (ja) |
NO (1) | NO310866B1 (ja) |
NZ (1) | NZ323389A (ja) |
PL (1) | PL326927A1 (ja) |
TR (1) | TR199800925T2 (ja) |
WO (1) | WO1997019928A1 (ja) |
ZA (1) | ZA969812B (ja) |
Families Citing this family (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9825554D0 (en) * | 1998-11-20 | 1999-01-13 | Smithkline Beecham Spa | Novel Compounds |
US7037922B1 (en) | 2000-03-10 | 2006-05-02 | Neurogen Corporation | Aryl fused 2,4-disubstituted pyridines: NK3 receptor ligands |
US6413982B1 (en) | 1999-03-29 | 2002-07-02 | Neurogen Corporation | 4-substituted quinoline derivatives |
AU4802500A (en) | 1999-04-26 | 2000-11-10 | Neurogen Corporation | 2-aminoquinolinecarboxamides: neurokinin receptor ligands |
AU2006253054A1 (en) * | 2005-06-03 | 2006-12-07 | Astrazeneca Ab | Quinoline derivatives as NK3 anatgonists |
GB0515580D0 (en) | 2005-07-29 | 2005-09-07 | Merck Sharp & Dohme | Therapeutic compounds |
EP1919871A4 (en) * | 2005-08-02 | 2010-08-18 | Glaxosmithkline Llc | PROCESS FOR SYNTHESIS OF CHINOLINE DERIVATIVES |
JP2009504642A (ja) * | 2005-08-11 | 2009-02-05 | アストラゼネカ・アクチエボラーグ | Nk−3受容体の調節剤としてのオキソピリジルキノリンアミド |
WO2007035156A1 (en) * | 2005-09-21 | 2007-03-29 | Astrazeneca Ab | N-oxo-heterocycle and n-oxo-alkyl quinoline-4-carboxamides as nk-3 receptor ligands |
AR057130A1 (es) * | 2005-09-21 | 2007-11-14 | Astrazeneca Ab | Quinolinas de alquilsulfoxido y una composicion farmaceutica |
TW201018662A (en) | 2005-12-12 | 2010-05-16 | Astrazeneca Ab | Alkylsulphonamide quinolines |
EP1981882A4 (en) * | 2006-01-27 | 2009-11-18 | Astrazeneca Ab | QUINOLINES SUBSTITUTED BY AN AMIDE |
FR2979173B1 (fr) * | 2011-08-19 | 2013-08-16 | St Microelectronics Grenoble 2 | Commutateur analogique basse tension |
US9278960B2 (en) | 2011-11-03 | 2016-03-08 | Merck Sharp & Dohme Corp. | Quinoline carboxamide and quinoline carbonitrile derivatives as mGluR2-negative allosteric modulators, compositions, and their use |
AU2014255512A1 (en) | 2013-04-19 | 2015-11-12 | Astrazeneca Ab | A NK3 receptor antagonist compound (NK3RA) for use in a method for the treatment of polycystic ovary syndrome (PCOS) |
WO2017072629A1 (en) | 2015-10-29 | 2017-05-04 | Cadila Healthcare Limited | Pharmaceutical combination of nk3 receptor antagonist and biguanides |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
HU226535B1 (en) | 1994-05-27 | 2009-03-30 | Glaxosmithkline Spa | Quinoline derivatives as tachykinin nk3 receptor antagonists, pharmaceutical compositions containing them, and their use |
IT1270615B (it) * | 1994-07-14 | 1997-05-07 | Smithkline Beecham Farma | Uso di derivati di chinolina |
-
1995
- 1995-11-24 GB GBGB9524137.8A patent/GB9524137D0/en active Pending
-
1996
- 1996-11-21 AR ARP960105281A patent/AR004970A1/es unknown
- 1996-11-22 AT AT96941026T patent/ATE233243T1/de not_active IP Right Cessation
- 1996-11-22 ZA ZA9609812A patent/ZA969812B/xx unknown
- 1996-11-22 WO PCT/EP1996/005210 patent/WO1997019928A1/en not_active Application Discontinuation
- 1996-11-22 IL IL12435296A patent/IL124352A0/xx unknown
- 1996-11-22 BR BR9611729A patent/BR9611729A/pt unknown
- 1996-11-22 CA CA002238312A patent/CA2238312A1/en not_active Abandoned
- 1996-11-22 CN CN96199611A patent/CN1207728A/zh active Pending
- 1996-11-22 HU HU9903584A patent/HUP9903584A3/hu unknown
- 1996-11-22 ES ES96941026T patent/ES2192621T3/es not_active Expired - Lifetime
- 1996-11-22 AU AU10319/97A patent/AU722451B2/en not_active Ceased
- 1996-11-22 TR TR1998/00925T patent/TR199800925T2/xx unknown
- 1996-11-22 JP JP52016097A patent/JP4377454B2/ja not_active Expired - Fee Related
- 1996-11-22 PL PL96326927A patent/PL326927A1/xx unknown
- 1996-11-22 US US09/077,152 patent/US6355654B1/en not_active Expired - Fee Related
- 1996-11-22 NZ NZ323389A patent/NZ323389A/en unknown
- 1996-11-22 DE DE69626416T patent/DE69626416T2/de not_active Expired - Lifetime
- 1996-11-22 KR KR1019980703875A patent/KR19990071599A/ko not_active Application Discontinuation
- 1996-11-22 EP EP96941026A patent/EP0876348B1/en not_active Expired - Lifetime
- 1996-11-22 CZ CZ981581A patent/CZ158198A3/cs unknown
-
1998
- 1998-05-22 MX MX9804106A patent/MX9804106A/es unknown
- 1998-05-22 NO NO19982332A patent/NO310866B1/no not_active IP Right Cessation
-
2001
- 2001-11-06 US US09/994,076 patent/US6432977B1/en not_active Expired - Fee Related
-
2002
- 2002-06-12 US US10/167,881 patent/US20020156097A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
AU722451B2 (en) | 2000-08-03 |
CZ158198A3 (cs) | 1998-10-14 |
US20020077335A1 (en) | 2002-06-20 |
TR199800925T2 (xx) | 2001-05-21 |
WO1997019928A1 (en) | 1997-06-05 |
MX9804106A (es) | 1998-09-30 |
GB9524137D0 (en) | 1996-01-24 |
HUP9903584A3 (en) | 2001-10-29 |
NO982332D0 (no) | 1998-05-22 |
IL124352A0 (en) | 1998-12-06 |
JP4377454B2 (ja) | 2009-12-02 |
PL326927A1 (en) | 1998-11-09 |
CN1207728A (zh) | 1999-02-10 |
NO982332L (no) | 1998-05-22 |
EP0876348B1 (en) | 2003-02-26 |
KR19990071599A (ko) | 1999-09-27 |
BR9611729A (pt) | 1999-04-06 |
CA2238312A1 (en) | 1997-06-05 |
AR004970A1 (es) | 1999-04-07 |
ZA969812B (en) | 1998-05-22 |
US6355654B1 (en) | 2002-03-12 |
DE69626416T2 (de) | 2003-12-24 |
US6432977B1 (en) | 2002-08-13 |
DE69626416D1 (de) | 2003-04-03 |
ES2192621T3 (es) | 2003-10-16 |
NO310866B1 (no) | 2001-09-10 |
HUP9903584A2 (hu) | 2000-02-28 |
US20020156097A1 (en) | 2002-10-24 |
AU1031997A (en) | 1997-06-19 |
EP0876348A1 (en) | 1998-11-11 |
NZ323389A (en) | 2000-02-28 |
ATE233243T1 (de) | 2003-03-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE69533408T2 (de) | Chinolinderivate als Tachykinin NK3 Rezeptor Antagonisten | |
EP0874827B1 (en) | Quinoline derivatives as nk3 antagonists | |
JP2000500770A (ja) | Nk3拮抗物質としてのキノリン誘導体の塩 | |
JP2000513325A (ja) | キノリン―4―カルボキシアミド誘導体、その製法およびそのニューロキニン3(nk―3)およびニューロキニン2(nk―2)レセプター・アンタゴニストとしての使用 | |
JP2002500645A (ja) | Nk−2およびnk−3レセプターアンタゴニストとしてのキノリン−4−カルボキシアミド誘導体 | |
JP2006117568A (ja) | チオフェン環を有する新規アミド誘導体及びその医薬としての用途 | |
RU2155754C2 (ru) | Производные хинолина как антагонисты nk3-рецептора тахикинина | |
JP2004517082A (ja) | Nk−3アンタゴニストとしてのキノリン誘導体 | |
ITMI950495A1 (it) | Derivati chinolinici | |
ITMI950494A1 (it) | Derivati chinolinici | |
KR20010012823A (ko) | Nk-2 및 nk-3 수용체 길항제로서의퀴놀린-4-카르복스아미드 유도체 | |
ITMI952459A1 (it) | Derivati chinolinici | |
AU5784501A (en) | Quinoline derivatives as tachykinin NK3 receptor antagonists | |
ITMI952462A1 (it) | Derivati chinolinici |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20031120 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20070612 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20070905 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20071015 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20071212 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20090310 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20090604 |
|
A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20090806 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20090825 |
|
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20090911 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 4377454 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20120918 Year of fee payment: 3 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20120918 Year of fee payment: 3 |
|
LAPS | Cancellation because of no payment of annual fees |